ConductScience.org, home

Comparison · NCT01539226-c49485d4

Dapivirine Vaginal Ring vs Placebo Vaginal Ring: HIV-1 Seroconversion According to Comprehensive HIV Testing Algorithm.

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Dapivirine Vaginal Ring vs Placebo Vaginal Ring: HIV-1 Seroconversion According to Comprehensive HIV Testing Algorithm. Trial comparisons, record NCT01539226-c49485d4. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01539226-c49485d4

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.0630.0510.0775wilson
Risk in group 20.09380.07380.119wilson
Risk difference, group 1 minus group 2-0.0309-0.0585-0.00607newcombe hybrid score
Risk ratio, group 1 over group 20.6710.4880.922log
Odds ratio, group 1 over group 20.6490.4590.917log
Number needed to treat, for one fewer participant with the outcome on Dapivirine Vaginal Ring than on Placebo Vaginal Ring32.417.1165from the risk difference interval

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Dapivirine Vaginal RingVaginal Ring containing 25mg of Dapivirine~Dapivirine Vaginal Ring, 25 mg: Dapivirine Vaginal Ring containing 25 mg of dapivirine821,302OG000
Group 2Placebo Vaginal RingVaginal Ring containing 0.0 mg Dapivirine~Placebo Vaginal Ring: Dapivirine Vaginal Ring containing 0.0 mg of dapivirine61650OG001

Outcome

Type
PRIMARY
Title
HIV-1 Seroconversion According to Comprehensive HIV Testing Algorithm.
Description
HIV-1 seroconversion measured by rapid and specialised laboratory testing according to the comprehensive HIV testing algorithm.
Time frame
24 months
Population
This population consisted of all participants included in the ITT population (all randomised), excluding those who were not identified as HIV-seropositive at the Enrollment Visit, but who were later found to be already HIV-1 infected at enrollment through HIV-1 RNA PCR testing.

Source ClinicalTrials.gov

Trial

Title
Safety and Efficacy Trial of a Dapivirine Vaginal Matrix Ring in Healthy HIV-Negative Women
NCT number
NCT01539226
Phases
NA
Conditions
HIV Infections
Interventions
Placebo Vaginal Ring, Dapivirine Vaginal Ring, 25 mg
Lead sponsor
International Partnership for Microbicides, Inc.
Results first posted
2022-10-19

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT01539226-c49485d4